Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 20

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 20
---
 that we will ever be able to do so, or that we may ever achieve profitability. The amount of the accumulated
deficit will continue to increase, as it will be expensive to continue research, development and clinical efforts. If these activities
are successful and if we receive positive results from the clinical trials and subsequently from the FDA to market our novel therapies,
then even more funding will be required to market those. The outcome of these matters cannot be predicted at this time. We expect to
expand our clinical trials significantly, which will result in increasing losses, and may continue to incur substantial losses before
we begin to generate revenues from the development and marketing of our technology. There can be no assurance that we successfully raise
additional funds and that we will achieve positive cash flow. If we are unable to raise additional funds under terms acceptable to us
and in the interests of our stockholders, then we will have to scale back or discontinuing one or more of our aspects of operations,
including stopping or delaying planned clinical trials.

We will need substantial additional funding to realize our business plan, due to a number of factors, some of which are beyond our control. We may not be able to raise capital when needed, if at all, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts and could cause our business to fail.

Our operations have consumed substantial amounts
of cash since inception. We expect our expenses to increase in connection with our ongoing activities. Our plan, which includes pre-clinical
and clinical efforts, conducting research, furthering development, continuing current and future pre-clinical and clinical trials will
require substantial funding. We may also seek to commercialize certain product candidates in the future, but there can be no assurance
that we will obtain regulatory approval or achieve commercialization. If we were to obtain regulatory approval for any of our product
candidates, we would likely incur additional significant expenses related to regulatory requirements, product manufacturing, marketing,
sales, and distribution.

Furthermore, we expect to incur additional costs
associated with operating as an SEC reporting public company. We may also encounter unforeseen expenses, difficulties, complications,
delays and other unknown factors that may increase our capital needs and/or cause us to spend our cash resources faster than we expect.

Until we can generate a sufficient amount of
product revenue to finance our cash requirements, which we may never achieve, we expect to finance our cash needs primarily through public
or private equity offerings, debt financings or through the establishment of possible strategic